In the follow-up, further efforts are needed to find potential therapeutic drugs for the treatment of AD animal models and to explore the regulatory mechanism of the drug on the E2F-1/NF-κB/GSK-3β pathway and Tau protein phosphorylation. Here, MAPT is linked to Alzheimer disease.